FDA grants approval for first generic version of Viagra

pharmafile | March 10, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing FDA, Pfizer, Teva, erectile dysfunction, generic, viagra 

The US Food and Drug Administration (FDA) has granted approval to the first generic version of Pfizer’s blockbuster erectile dysfunction drug, Viagra (sildenafil citrate).

Israeli-based Teva Pharmaceuticals has received the approval, but have also agreed a deal with Pfizer to delay bringing the generic to market until December 2017. Reuters reported a similar deal struck between Pfizer and Mylan, with the latter’s generic still subject to FDA approval.

Teva has gained approval for the drug at 25mg, 50mg and 100mg doses. It previously launched its Viagra generic in the EU in 2013.

Advertisement

Teva will pay royalties through to the expiration of the Viagra patent in the US in April 2020.

Sean Murray

Related Content

Teva announces positive results from trial of AJOVY for migraine

Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

Rethinking oncology trial endpoints with generalised pairwise comparisons

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

brain_anatomy_medical_head_skull_digital_3_d_x_ray_xray_psychedelic_3720x2631_1

Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation

Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …

The Gateway to Local Adoption Series

Latest content